SCHEMBL2279853

SCHEMBL2279853

COCCNC(=O)c1cccc(C=CC(=O)c2c(O)cc(C)n(C)c2=O)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HB P07237 4/20 0.41
HPGD P15428 5/20 0.41
CYP2C19 P33261 2/20 0.41
CYP1A2 P05177 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.39
CYP19A1 P11511 1/20 0.39
CYP2C9 P11712 1/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2279851 1.00 P4HB (0.41) P4HBHPGDCYP2C19CYP1A2NPC1
SCHEMBL2277707 0.90 NPC1 (0.42) P4HBNPC1RAB9AKDM4EABCG2
SCHEMBL2277708 0.90 NPC1 (0.42) P4HBNPC1RAB9AKDM4EABCG2
SCHEMBL2278482 0.90 KDM4E (0.43) P4HBHPGDCYP2C19CYP1A2ALDH1A1
SCHEMBL2278483 0.90 KDM4E (0.43) P4HBHPGDCYP2C19CYP1A2ALDH1A1
SCHEMBL2281269 0.89 P4HB (0.41) P4HBCYP2C19NPC1RAB9AABCG2
SCHEMBL2281265 0.89 P4HB (0.41) P4HBCYP2C19NPC1RAB9AABCG2
SCHEMBL2284349 0.87 NPC1 (0.42) P4HBCYP2C19NPC1RAB9ACYP19A1
SCHEMBL2284353 0.87 NPC1 (0.42) P4HBCYP2C19NPC1RAB9ACYP19A1
SCHEMBL2281180 0.86 P4HB (0.44) P4HBCYP2C19NPC1RAB9AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 P4HB 702/4885HPGD 1011/4885CYP2C19 4627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.